Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Switching biologics in the treatment of psoriatic arthritis
Joseph F. Merola, Benjamin Lockshin, Elinor Mody
Seminars in Arthritis and Rheumatism (2017) Vol. 47, Iss. 1, pp. 29-37
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, et al.
The Lancet (2020) Vol. 395, Iss. 10230, pp. 1115-1125
Open Access | Times Cited: 263
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip J. Mease, Laura C. Coates, Philip Helliwell, et al.
The Lancet (2018) Vol. 392, Iss. 10162, pp. 2367-2377
Open Access | Times Cited: 188
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 3, pp. 475-485
Open Access | Times Cited: 73
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C. Coates, Laure Gossec, Elke Theander, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 359-369
Open Access | Times Cited: 69
Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database
Laura Pina Vegas, Laëtitia Penso, Pascal Claudepierre, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 5, pp. 513-513
Open Access | Times Cited: 46
The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis
Shigeru Kotake, Toru Yago, Tsuyoshi Kobashigawa, et al.
Journal of Clinical Medicine (2017) Vol. 6, Iss. 7, pp. 67-67
Open Access | Times Cited: 75
Psoriatic arthritis for dermatologists
Alice B. Gottlieb, Joseph F. Merola
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 7, pp. 662-679
Open Access | Times Cited: 72
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Luisa Costa, Carlo Perricone, Maria Sole Chimenti, et al.
Drugs in R&D (2017) Vol. 17, Iss. 4, pp. 509-522
Open Access | Times Cited: 71
Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States
April W. Armstrong, Manish Patel, Chao Li, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 22
Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals
André Lucas Ribeiro, Shikha Singla, Vinod Chandran, et al.
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 7
Systemic therapies of pityriasis rubra pilaris: a systematic review
Christian Kromer, Robert Sabat, Daniel Celis, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2018) Vol. 17, Iss. 3, pp. 243-259
Closed Access | Times Cited: 54
Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database
Kurt Oelke, Olivier Chambenoit, Amar Q Majjhoo, et al.
Journal of Comparative Effectiveness Research (2019) Vol. 8, Iss. 8, pp. 607-621
Open Access | Times Cited: 47
Total-Body 18F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations
Yasser G. Abdelhafez, S. P. Raychaudhuri, Dario F. Mazza, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 10, pp. 1579-1585
Open Access | Times Cited: 24
Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
Cécile Philippoteaux, A. Marty-Ane, Émeline Cailliau, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 63, pp. 152275-152275
Open Access | Times Cited: 14
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Philip J. Mease, Dafna D. Gladman, Joseph F. Merola, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 7, pp. 1779-1789
Open Access | Times Cited: 5
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database
Jessica A. Walsh, Oluwakayode Adejoro, Benjamin Chastek, et al.
Journal of Managed Care & Specialty Pharmacy (2018) Vol. 24, Iss. 7, pp. 623-631
Open Access | Times Cited: 39
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Christopher T. Ritchlin, Philip J. Mease, Wolf‐­Henning Boehncke, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002195-e002195
Open Access | Times Cited: 21
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis
Proton Rahman, Wolf‐­Henning Boehncke, Philip J. Mease, et al.
The Journal of Rheumatology (2023) Vol. 50, Iss. 6, pp. 769-780
Open Access | Times Cited: 13
Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
Philip J. Mease, Chitra Karki, Mei Liu, et al.
RMD Open (2019) Vol. 5, Iss. 1, pp. e000880-e000880
Open Access | Times Cited: 34
Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
Hideto Kameda, Kentaro Ishii, Junna Kiriyama, et al.
Rheumatology and Therapy (2025)
Open Access
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
Alexis Ogdie, Soumya M. Reddy, Susan Gillespie, et al.
Trials (2025) Vol. 26, Iss. 1
Open Access
Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice
Leticia León, D. Freites, Esther Toledano, et al.
Therapeutic Advances in Musculoskeletal Disease (2025) Vol. 17
Open Access
Biologic Switching in Psoriatic Arthritis: Insights from Real-World Data and Key Risk Factors
Amir Haddad, Nili Stein, Ilan Feldhamer, et al.
Seminars in Arthritis and Rheumatism (2025) Vol. 73, pp. 152737-152737
Open Access
Difficult‐to‐Treat Psoriatic Arthritis: A Conceptual Approach
Filippo Fagni, Francesca Motta, Georg Schett, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 670-674
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top